The Challenge of Improving - BrokerBank Securities

NEW YORK, July 16, 2015 /PRNewswire/ -- Arena Pharmaceuticals Incorporation (NASDAQ: ARNA) is a biopharmaceutical company focused on discovering, developing, and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. The company's internally discovered drug, lorcaserin, is approved by the US Food and Drug Administration (FDA) for chronic weight management in adults. Lorcaserin was available by prescription in June 2013 to adults who are overweight with comorbidity or obese, under the brand name BELVIQ.

Recently, when Celgene made an offer to buyout Receptos for $6.7 billion in cash, Arena Pharmaceuticals got a 7% shot in the arm due to the fact that Receptos and Arena are exploring drug candidates in the same realm. In case, Arena, valued at about $1 billion, could see substantial upside if its own drug candidates advance.

An analyst brief and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report.

http://bit.ly/-ARNA_AnalystReport

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.  

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. This report was prepared for informational purposes only.  Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company.  A full disclaimer can be found by viewing the full analyst report. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-challenge-of-improving--brokerbank-securities-300114226.html

SOURCE BrokerBank Securities, Inc.